The latest price target for Silexion Therapeutics (NASDAQ:SLXN) was reported by Maxim Group on November 1, 2024. The analyst firm set a price target for $1.00 expecting SLXN to fall to within 12 months (a possible -58.33% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Silexion Therapeutics (NASDAQ:SLXN) was provided by Maxim Group, and Silexion Therapeutics initiated their buy rating.

There is no last upgrade for Silexion Therapeutics

There is no last downgrade for Silexion Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Silexion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Silexion Therapeutics was filed on November 1, 2024 so you should expect the next rating to be made available sometime around November 1, 2025.

While ratings are subjective and will change, the latest Silexion Therapeutics (SLXN) rating was a initiated with a price target of $0.00 to $1.00. The current price Silexion Therapeutics (SLXN) is trading at is $2.40, which is out of the analyst’s predicted range.